Pfizer's Q1 2025 Financial report

Pfizer Q1 2025 Financial Report Analysis

Recently, Pfizer announced its financial results for the first quarter of 2025 and reaffirmed its full-year guidance. Despite a complex market environment, the company achieved solid profit growth through strengthened R&D organization and cost optimization measures.

Financial Highlights

• Total Revenue: $13.7 billion, down 8% year-over-year (6% decline on a constant currency basis), primarily due to a 75% decrease in Paxlovid revenue, partially offset by growth in products like the Vyndaqel series (up 33%) and Comirnaty (up 62%).

• Adjusted EPS: $0.92, up 12% year-over-year, approaching the upper end of the full-year guidance range ($2.80–$3.00).

• Cost Savings Plan: Targeting $4.5 billion in net cost savings by the end of 2025, with an additional $1.2 billion savings goal by 2027, $500 million of which will come from R&D restructuring.

Management Commentary

Pfizer Chairman and CEO Dr. Albert Bourla stated: “We continue to advance our strategic priorities, including optimizing R&D efficiency and business agility to navigate an uncertain external environment.” CFO David Denton added: “Our first-quarter performance demonstrates our ability to execute under healthcare policy pressures. Improved operational efficiency positions us to meet our full-year profitability goals.”

Business Performance

• Growth Drivers: Vyndaqel (for transthyretin amyloid cardiomyopathy), Comirnaty (COVID-19 vaccine), Padcev (urothelial cancer drug), and Nurtec ODT (migraine treatment) all posted double-digit growth.
• Declining Factors: Paxlovid revenue plummeted due to U.S. government return adjustments and lower demand. Eliquis (anticoagulant) and Ibrance (breast cancer drug) declined due to generic competition and insurance discounts.

R&D and Pipeline Progress

• Product Milestones: Abrysvo (RSV vaccine) received EU approval for expansion to the 18–59 age group, and a U.S. advisory committee recommended lowering the eligible age to 50 for high-risk adults. The Phase III trial of Padcev combined with Keytruda showed sustained survival benefits with good safety profile.
• Pipeline Adjustments: Discontinued development of oral GLP-1 receptor agonist danuglipron for obesity; refocusing on other cardiovascular and metabolic disease programs.

Capital Allocation

• R&D Investment: $2.2 billion invested in internal R&D and $90 million in business development.
• Shareholder Returns: $2.4 billion in quarterly dividends ($0.43 per share); $3.3 billion remaining in authorized share repurchases, though no buybacks are included in the 2025 guidance.

2025 Financial Guidance

Reaffirmed full-year revenue forecast of $61–64 billion and adjusted EPS of $2.80–$3.00, excluding potential impacts from tariff policy changes.